Financial Performance - Ashland's Q1 FY23 sales increased by 3% to $525 million compared to $512 million in Q1 FY22[15, 22] - The company's EBITDA for Q1 FY23 rose by 2% to $108 million, slightly up from $106 million in Q1 FY22[15, 22] - EPS (excluding acquisition amortization) increased by 10% to $0.97 from $0.88 year-over-year[15, 22] - Gross profit margin remained consistent at 31.4%[22] Segment Performance - Life Sciences sales grew significantly by 22% to $207 million, up from $170 million, with a 44% increase in EBITDA to $52 million[15, 24] - Personal Care sales decreased by 6% to $138 million from $147 million, and EBITDA decreased by 11% to $32 million[26] - Specialty Additives experienced an 8% decrease in sales to $143 million from $156 million, with a 39% drop in EBITDA to $23 million[28] - Intermediates sales increased by 2% to $54 million from $53 million, with a 21% increase in EBITDA to $23 million[30] Key Factors and Outlook - The company is maintaining its full-year guidance with sales expected to be in the range of $2.5 - $2.7 billion and adjusted EBITDA between $600 - $650 million[39] - Unfavorable FX impacted sales and EBITDA in multiple segments, including Life Sciences (5% and 19% respectively), Personal Care (5% and 8% respectively), and Specialty Additives (4% and 3% respectively)[24, 26, 28]

Ashland Inc. (NYSE:ASH) Q1 2023 Earnings Conference Call February 1, 2022 9:00 AM ET Company Participants Seth Mrozek - Director, IR Guillermo Novo - Chairman & CEO Kevin Willis - SVP & CFO Conference Call Participants Christopher Parkinson - Mizuho Securities Joshua Spector - UBS David Begleiter - Deutsche Bank John McNulty - BMO Capital Markets Mike Harrison - Seaport Research Partners John Roberts - Credit Suisse Jeffrey Zekauskas - JPMorgan Michael Sison - Wells Fargo Laurence Alexander - Jefferies Oper ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-211719 ASHLAND INC. (a Delaware corporation) I.R.S. No. 81-2587835 8145 Blazer Drive Wilmington, Delaware 19808 Telephone Num ...

Ashland Global Holdings Inc. (NYSE:ASH) Q3 2022 Earnings Conference Call July 27, 2022 9:00 AM ET Company Participants Seth Mrozek - Director, IR Guillermo Novo - Chairman and CEO John Willis - SVP and CFO Conference Call Participants Christopher Parkinson - Mizuho Joshua Spector - UBS John McNulty - BMO Capital Markets David Begleiter - Deutsche Bank Mike Harrison - Seaport Research Partners Michael Sison - Wells Fargo Operator Thank you for standing by. Welcome to the Ashland Global Holdings Inc. Third Qu ...

Call Start: 09:00 January 1, 0000 10:08 AM ET Ashland Global Holdings Inc (NYSE:ASH) Q2 2022 Earnings Conference Call April 27, 2022, 9:00 AM ET Company Participants Guillermo Novo – Chairman and Chief Executive Officer John Kevin Willis – Senior Vice President and Chief Financial Officer Seth Mrozek – Director of Investor Relations Conference Call Participants John McNulty – Bank of Montreal Capital Markets Christopher Parkinson – Mizuho Josh Spector – Union Bank of Switzerland David Begleiter – Deutsche B ...